WestPark Capital initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $48 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics assumed with a Buy at Jefferies
- Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)
- ALGS Earnings this Week: How Will it Perform?
- Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
- Aligos announces data from two presentations at CROI on pevifoscorvir sodium